National Health Act (Pharmaceutical Benefits Early Supply) Amendment December 2012 specification under subsection 84AAA(2) (No. PB 104 of 2012) (Cth)
COMMONWEALTH OF AUSTRALIA
Instrument number PB 104 of 2012
National Health Act (Pharmaceutical Benefits – Early Supply) Amendment December 2012 - specification under subsection 84AAA(2)1
Amendment determination under subsection 84AAA(2) of the National Health Act 1953
I, Adriana Platona, Assistant Secretary, Pharmaceutical Evaluation Branch, Department of Health and Ageing, delegate of the Minister for Health, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.
Dated 27 November 2012
ADRIANA PLATONA
Assistant Secretary
Pharmaceutical Evaluation Branch
Department of Health and Ageing
Amendment determination — Pharmaceutical Benefits - Early Supply
1 Name of Instrument
(1) This Instrument is the National Health Act (Pharmaceutical Benefits – Early Supply) Amendment December 2012 - specification under subsection 84AAA(2).
(2) This Instrument may also be cited as No. PB 104 of 2012.
2 Commencement
This Instrument commences on 1 December 2012.
3 Amendment of PB 30 of 2009
Schedule 1 amends the National Health (Pharmaceutical Benefits – Early Supply) Instrument 2009- specification under subsection 84AAA(2), PB 30 of 2009.
Schedule 1 Amendments
Schedule 1, entry for Atenolol, after the form Tablet 50 mg
insert in the columns in the order indicated:
| Oral solution 50 mg in 10 mL, 300 mL | Oral | 1 | 5 |
Schedule 1, entry for Pazopanib
substitute:
| Pazopanib | Tablet 200 mg (as hydrochloride) | Oral | 30 | 5 |
| 90 | 5 | |||
| Tablet 400 mg (as hydrochloride) | Oral | 30 | 5 | |
| 60 | 5 |
Schedule 1, after entry for Risedronic acid and calcium with colecalciferol
insert in the columns in the order indicated:
| Rivaroxaban | Tablet 20 mg | Oral | 28 | 5 |
1Note
All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003.
See
0
0
0